PanGen Biotech Inc Cash Flow Quality Index

Latest as of September 2025: -6.88x

PanGen Biotech Inc cash flow quality index. PanGen Biotech Inc (222110) has a Cash Flow Quality Index of -6.88x as of September 2025. Operating cash flow of ₩-3.66 Billion is below net income of ₩531.94 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial agility of PanGen Biotech Inc to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

-6.88x

Operating CF / Net Income

Operating Cash Flow

₩-3.66 Billion

KRW

Net Income

₩531.94 Million

KRW

Data as of

Sep 2025

Most recent filing

Cash Flow Quality Index of PanGen Biotech Inc (2024–2024)

Cash flow quality index of PanGen Biotech Inc from 2024 to 2024. Historical Cash Flow Quality Index for PanGen Biotech Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore cash flow to debt ratio of PanGen Biotech Inc to assess how comfortably operating cash covers total debt obligations.

PanGen Biotech Inc Cash Flow Quality Index by Year (2024–2024)

PanGen Biotech Inc cash flow quality index by year from 2024 to 2024. Year-by-year earnings quality comparison for PanGen Biotech Inc. For the full cash flow conversion analysis, see 222110 cash flow metrics.

Year	Quality Index	Operating CF (KRW)	Net Income	YoY Change
2024	3.17x	₩2.99 Billion	₩943.69 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.